相关实验视频
Updated: Jul 6, 2025

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
119
乔尔基诺利德B通过调节JAK2/STAT3信号通路来改善类风湿性关节炎
Yu Yan1, Liu-Bo Zhang2, Ru Ma3
1Department of TCM Rheumatism, Department of Pharmacy & Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, 2 Yinghuayuan East Street, Chaoyang District, Beijing 100029, PR China.
概括
乔尔基诺利德B (JB) 通过抑制炎症和骨破坏,有效治疗类风湿性关节炎 (RA). 它的机制涉及调节JAK2/STAT3信号通路,为RA提供潜在的向治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 乔尔基诺利德B (JB) 是一种来自Euphorbia植物的二类物质,具有抗癌,抗炎和抗结核性质.
- 之前的研究尚未确定JB在治疗类风湿性关节炎 (RA) 中的疗效或机制.
研究的目的:
- 评估Jolkinolide B (JB) 的抗风湿性关节炎 (RA) 作用.
- 阐明JB抗RA活性背后的潜在分子机制.
主要方法:
- 使用数据库识别了JB和RA目标;通过PPI和丰富分析预测了路径.
- 使用分子对接和表面等离子体共振 (SPR) 验证的目标和途径.
- 评估了JB的抗关节炎作用 in vivo (原诱导的关节炎大鼠) 和 in vitro (巨细胞模型).
主要成果:
- 凯格分析表明,JB的抗RA作用涉及Th17细胞分化和JAK/STAT信号传递.
- 分子对接和SPR证实JB与JAK2.2结合.
- 在实验室中,JB治疗减少了老鼠的RA症状和炎症标志物,抑制了JAK2/STAT3通路.
结论:
- 乔尔基诺利德B (JB) 在原诱导性关节炎的老鼠模型中显示出显著的抗炎和抗骨破坏作用.
- 在RA中JB的治疗机制与JAK2/STAT3信号通路的抑制有关.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127

